INZY NASDAQ
Inozyme Pharma, Inc.
1W: +0.2%
1M: +0.5%
3M: +359.8%
1Y: -10.3%
3Y: -22.5%
$4.00
Last traded 2025-07-02 — delisted
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Smart Money Score
No convergence signal
Key Statistics
Market Cap$258.2M
52W Range0.721-6.24
Volume1,459,443
Avg Volume2,209,767
Beta2.29
Dividend—
Analyst Ratings
Company Info
CEODouglas A. Treco
Employees67
SectorHealthcare
IndustryBiotechnology
IPO Date2020-07-24
Websiteinozyme.com
321 Summer Street
Boston, MA 02210
US
Boston, MA 02210
US
857 330 4340
About Inozyme Pharma, Inc.
Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, as well as for the treatment of calciphylaxis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. Inozyme Pharma, Inc. was incorporated in 2015 and is headquartered in Boston, Massachusetts.
Latest News
No recent news
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Subramanian Sanjay | D-Return | 180,000 | $3.96 | 2025-07-01 |
| Subramanian Sanjay | D-Return | 135,000 | $3.30 | 2025-07-01 |
| Subramanian Sanjay | D-Return | 145,000 | $1.06 | 2025-07-01 |
| Subramanian Sanjay | U-Tender | 39,701 | $4.00 | 2025-07-01 |
| Subramanian Sanjay | D-Return | 38,500 | — | 2025-07-01 |